EMEA-002958-PIP01-21-M01 - paediatric investigation plan
Aficamten
PIPHuman
Key facts
- Active Substance
- Aficamten
- Therapeutic area
- Congenital, familial and genetic disorders
- Decision number
- P/0123/2024
- PIP number
- EMEA-002958-PIP01-21-M01
- Pharmaceutical form(s)
- Tablet
- Condition(s) / indication(s)
- Treatment of hypertrophic cardiomyopathy
- Route(s) of administration
- Oral use
- Contact for public enquiries
Cytokinetics, Inc.
Tel.: +1 650 624 3000
E-mail: regaffairs@cytokinetics.com- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date